KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Arbutus Biopharma (ABUS) over the last 15 years, with Q3 2025 value amounting to $844000.0.

  • Arbutus Biopharma's Cash from Financing Activities fell 5245.07% to $844000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 8988.27%. This contributed to the annual value of $52.0 million for FY2024, which is 6966.1% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Cash from Financing Activities of $844000.0 as of Q3 2025, which was down 5245.07% from $453000.0 recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Cash from Financing Activities ranged from a high of $59.1 million in Q4 2021 and a low of $113000.0 during Q2 2022
  • For the 5-year period, Arbutus Biopharma's Cash from Financing Activities averaged around $13.5 million, with its median value being $4.7 million (2023).
  • In the last 5 years, Arbutus Biopharma's Cash from Financing Activities surged by 409646.02% in 2023 and then tumbled by 9814.12% in 2025.
  • Arbutus Biopharma's Cash from Financing Activities (Quarter) stood at $59.1 million in 2021, then crashed by 81.25% to $11.1 million in 2022, then crashed by 65.65% to $3.8 million in 2023, then tumbled by 62.67% to $1.4 million in 2024, then tumbled by 40.61% to $844000.0 in 2025.
  • Its Cash from Financing Activities was $844000.0 in Q3 2025, compared to $453000.0 in Q2 2025 and $2.8 million in Q1 2025.